Hector-Study to Evaluate the Efficacy of Octreotide in Patients With Inoperable Hepatocellular Carcinoma

Inclusion Criteria:

* Inoperable patients
* histologically confirmed HCC or patients who refuse surgery and who otherwise (e.g. due to the advanced tumor stage) are not applicable for palliative local therapy (e.g. PEI, TACE, RFTA).
* Age: 18 years or older

Exclusion Criteria:

General:

* Patient with symptomatic Cholecyst-/Choledocholithiasis
* Patient with severe psychiatric disease.
* Participation in another clinical trial within the last 4 weeks.
* Simultaneous participation in another clinical examination.
* Legally incapacitated patient, who is not able, to understand nature, meaning and consequence of the study.
* Continuous drug or alcohol abuse.
* Patient with known HIV infection and antiretroviral therapy.
* Patient with not controllable infection disease.
* Pregnancy.

Study- and indication-specific exclusion criteria:

* Secondary malignant tumor without complete remission.
* Secondary malignant tumor with complete remission but current adjuvant therapy.
* Preliminary or current therapy with tamoxifen
* Pretreatment of the HCC.
* First-time diagnosis \> 6 months before inclusion into the study.
* Severe hepatic encephalopathy, refractory to any treatment.
* Patients with operable HCC.
* Contraindication to i.m. injections.
* Hypersensitivity to octreotide.